The Food and Drug Administration is requiring manufacturers of widely used GLP-1 medications, including household names like Ozempic and Wegovy, to add new warning labels to their packaging following reports of a rare but serious side effect. The agency warns that these treatments for obesity and diabetes may be linked to a condition known as non-arteritic anterior ischemic optic neuropathy, which restricts blood flow to the optic nerve and can result in permanent blindness.
This safety directive follows an extensive review conducted by FDA scientists who analyzed data from 126 clinical trials involving more than 134,000 patients. Their meta-analysis revealed that users of GLP-1 drugs experienced the eye condition at a slightly higher rate than those taking placebos or alternative glucose-lowering medications. Specifically, researchers found about six cases per 100,000 patients annually, suggesting a nearly 68 percent increase in risk for those on these specific drugs.
Despite the warnings, federal health officials emphasized that the actual occurrence of this complication is extremely low, affecting only about 0.01 percent of participants in certain studied groups. Determining a direct cause remains challenging because many people prescribed these medications already suffer from high blood pressure, sleep apnea, and diabetes, all of which are independent risk factors for vision loss. Consequently, the FDA noted that while there is a correlation, they have not yet established a definitive causal link between the medicine and the injury.
For those currently using these injectables or pills, doctors say the condition typically affects adults over age 50 and manifests as sudden, painless vision loss in one eye upon waking up. Patients might notice blind spots, distorted colors or general blurring. While some individuals see partial spontaneous improvement over time, there is currently no proven medical treatment to fully reverse the damage once it occurs.
